miR-337 suppresses cutaneous T-cell lymphoma via the STAT3 pathway

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cutaneous T-cell lymphoma (CTCL) is characterized by the downregulation of microRNA-337 (miR-337) expression.
• The precise molecular mechanisms and functional consequences of miR-337 dysregulation in CTCL remain largely unknown.

Purpose of the Study:

• To investigate the molecular mechanisms underlying miR-337 downregulation in CTCL.
• To elucidate the functional role of miR-337 in regulating CTCL cell viability and invasion.
• To identify potential therapeutic targets for CTCL based on the miR-337 pathway.

Main Methods:

• Quantitative real-time PCR to assess miR-337 expression levels in CTCL tumors and cell lines.
• Cell viability assays (CCK, BrdU incorporation) and flow cytometry to evaluate proliferation and apoptosis.
• Transwell migration assays to assess *in vitro* invasion.
• Bioinformatics prediction and dual-luciferase reporter assays to identify and validate miR-337 targets.
• Overexpression studies of STAT3 to confirm its role in the miR-337 pathway.

Main Results:

• miR-337 expression was significantly downregulated in CTCL tumors and cell lines.
• Transfection with a miR-337 mimic reduced CTCL cell proliferation and enhanced apoptosis.
• miR-337 mimic transfection decreased CTCL cell invasion *in vitro*.
• STAT3 was identified as a direct target of miR-337, with miR-337 silencing STAT3 expression.
• Overexpression of STAT3 reversed the pro-apoptotic effects of miR-337 and restored CTCL cell invasion.

Conclusions:

• The miR-337-STAT3 axis plays a critical role in inhibiting the proliferation and invasion of malignant T cells in CTCL.
• miR-337 functions as a tumor suppressor in CTCL by targeting STAT3.
• miR-337 represents a promising novel therapeutic target for the treatment of cutaneous T-cell lymphoma.